ArthVue logoArthVue

Pharma · investment research

Dr. Reddy's Labs

DRREDDY

Price & statements

Verdict

AVOID

low confidence · 3-5 years

Composite score

41/100

Weighted across all eight pillars

Business quality

43/100

Moat, returns, balance sheet, cash, management

Valuation score

34/100

At 70.5x against a sector median of 70.5x, the price embeds roughly 53% earnings growth. Anything less has to come out of the multiple.

Decision intelligence

Every conclusion states what would make it wrong

WHAT

Avoid for now — the business or governance risk outweighs the opportunity.

WHY

  • • Balance sheet scores 0/100 (improving) — Leverage is high enough that a demand shock becomes a solvency question.
  • • Cash conversion scores 89/100 (stable) — Reported profit is backed by operating cash.
  • • Growth quality scores 22/100 (deteriorating) — Top-line compounding over the reported history.
  • • Management & governance scores 25/100 (stable) — Whether management historically delivered what it promised.

WHERE

Pharma · Small cap · position sized to at most 0% of an equity portfolio.

WHEN

Re-run this analysis after the next quarterly result.

WHAT IF WRONG

  • • The thesis is wrong if ROCE falls below 15% or cash conversion stays under 70% for two straight quarters.
  • • Valuation support fails below ₹1,871 of fair value — a drawdown to that level is a re-underwrite, not automatically a buy.
  • • Watched risk: Leverage — Debt is 6.7x EBITDA.

WHAT NEXT

  • • Read the latest quarterly cash-flow statement alongside the P&L.
  • • Check USFDA actions — it moves the earnings base independently of execution.
  • • Compare against the sector peers listed below before sizing anything.

Dr. Reddy's Labs is a competitively exposed pharma business compounding revenue at 9.7% and profit at -6.9%, earning 18.6% on capital. Quality scores 43/100 and valuation 34/100 at 70.5x. The decision is therefore avoid with low confidence — this is analysis for learning, not investment advice.

What does this business actually do?

Business understanding before ratios

Dr. Reddy's Labs operates in the Indian pharma sector with a small-cap footprint and a listed market value of about ₹107k Cr.

Revenue is earned across 4 reported segments; profitability is driven by realisations, mix and operating leverage rather than one-off items.

Revenue drivers

  • • Volume growth in the core segment
  • • Realisation / pricing power
  • • Mix shift toward higher-margin lines
  • • Capacity utilisation

Cost drivers

  • • Raw material and input costs
  • • Employee cost inflation
  • • Interest cost on borrowings
  • • Distribution and marketing spend

Moat · 49/100

Brand & distribution

Shelf presence and recall let the company hold price through input cost cycles.

Segment mix

India formulations20.8%

Growth 35.1% · margin 16.9% — Fastest growing part of the mix — watch whether margins hold as it scales.

US generics37.5%

Growth -7.8% · margin 21.2% — Flat to declining; drags the consolidated growth rate.

Emerging markets25.4%

Growth -1.7% · margin 8.4% — Flat to declining; drags the consolidated growth rate.

API & CRAMS16.4%

Growth 30.4% · margin 12.1% — Fastest growing part of the mix — watch whether margins hold as it scales.

Analysis pillars

Score, trend and the drivers behind each — no bare numbers

Business & moat

48/100

Trend: deteriorating · weight 14%

  • MoatBrand & distribution

    Shelf presence and recall let the company hold price through input cost cycles.

  • Segment concentrationIndia formulations is 20.8% of revenue

    Revenue is spread across segments, which softens single-market shocks.

  • EBITDA margin18.0%

    Margin moved from 22.0% to 18.0% year on year.

Profitability & returns

51/100

Trend: improving · weight 16%

  • ROCE18.6%

    ROCE was 16% a year ago. Sustained ROCE above the cost of capital is what compounds value.

  • ROE16.1%

    Return on equity after leverage — read alongside debt levels.

  • Net margin10.4%

    Share of every rupee of revenue that reaches reported profit.

Growth quality

22/100

Trend: deteriorating · weight 15%

  • Revenue CAGR (4y)9.7%

    Top-line compounding over the reported history.

  • Profit CAGR (4y)-6.9%

    Profit lags revenue, so growth is being bought with margin.

  • Growth sourceAsset-light / incremental

    Capex is 5.0% of revenue this year.

Balance sheet

0/100

Trend: improving · weight 12%

  • Debt / EBITDA6.69x

    Leverage is high enough that a demand shock becomes a solvency question.

  • Debt / equity1.88x

    Capital structure relative to shareholder funds.

  • Working capital98 days

    Long cycle: each rupee of growth locks up more cash.

Cash conversion

89/100

Trend: stable · weight 13%

  • OCF / PAT117%

    Reported profit is backed by operating cash.

  • Free cash flow₹2,654 Cr

    Cash left after maintaining and expanding the asset base.

Management & governance

25/100

Trend: stable · weight 14%

  • Guidance delivery50% of last 8 quarters

    Whether management historically delivered what it promised.

  • Promoter holding26.1% (+0.14 y/y)

    Promoter ownership is stable or rising.

  • Pledge21.5% pledged

    Pledged promoter shares add forced-selling risk in a drawdown.

  • Institutional flowFII +2.14 · DII +2.98

    Direction of institutional ownership over the last year.

  • Capital allocationGrowth has been part-funded with debt; increment…

    Growth has been part-funded with debt; incremental returns need to clear the cost of that debt.

Industry & macro

60/100

Trend: improving · weight 8%

  • Demand trendimproving

    Pharma (India) demand is improving.

  • StructureFragmented

    Fragmented — share shifts are possible but price competition is real.

  • Competitive intensitymedium

    How hard it is to keep pricing and share.

  • Macro driversUSFDA actions, US price erosion, API input costs

    Variables that move the earnings base regardless of company execution.

Valuation

34/100

Trend: stable · weight 8%

  • P/E vs sector70.5x vs 70.5x

    At 70.5x against a sector median of 70.5x, the price embeds roughly 53% earnings growth. Anything less has to come out of the multiple.

  • Growth-adjusted70.50 (PE/growth)

    Below ~1.5 the multiple is supported by growth; above ~2.5 it depends on the market staying optimistic.

  • FCF yield2.48%

    Cash return on the current market value, before any growth.

Financial history

Profit, cash and returns over five reported years

YearRevenueEBITDAPATOCFFCFROCE
FY2022₹25,416 Cr₹8,387 Cr₹5,116 Cr₹5,576 Cr₹4,305 Cr14.7%
FY2023₹28,256 Cr₹4,521 Cr₹2,939 Cr₹3,262 Cr₹-411 Cr19.1%
FY2024₹31,096 Cr₹6,841 Cr₹4,652 Cr₹5,257 Cr₹3,702 Cr19.4%
FY2025₹33,936 Cr₹7,466 Cr₹4,853 Cr₹5,581 Cr₹2,527 Cr16%
FY2026₹36,776 Cr₹6,620 Cr₹3,840 Cr₹4,493 Cr₹2,654 Cr18.6%
  • ⚠ Working capital cycle is long; growth consumes cash.

Ownership & management

Who owns it, and have they delivered?

Promoter

26.1%

+0.14 y/y

Pledge

21.5%

Forced-selling risk

FII

6.1%

+2.14 y/y

DII

4.6%

+2.98 y/y

Guidance delivered in 50% of the last eight quarters; average leadership tenure 5 years.

Growth has been part-funded with debt; incremental returns need to clear the cost of that debt.

  • ⚠ Related-party transactions at 5.2% of revenue

Industry & macro context

Pharma (India)

Demand trend

improving

Cyclicality

high

Competition

medium

Regulatory pressure

high

Fragmented — share shifts are possible but price competition is real.

Macro drivers: USFDA actions · US price erosion · API input costs

Valuation

fair versus the sector

P/E

70.5x

Sector median P/E

70.5x

P/B

1.55x

Earnings yield

1.42%

FCF yield

2.48%

PE / growth

70.5

Estimated fair-value band ₹1,871 – ₹2,391 , built on FY2026 EPS of ₹46.2. Gap to the current price: +65.5%. Ranges are a modelling output, not a target price.

At 70.5x against a sector median of 70.5x, the price embeds roughly 53% earnings growth. Anything less has to come out of the multiple.

Risk register

What can break the thesis, and how it is monitored

  • Leveragehigh

    Debt is 6.7x EBITDA.

    Monitor: Quarterly gross debt and interest coverage.

  • Promoter pledgehigh

    21.5% of promoter holding is pledged.

    Monitor: Pledge disclosures with each shareholding filing.

  • Cyclicalitymedium

    Pharma (India) earnings swing with the cycle, so trailing numbers flatter the peak.

    Monitor: USFDA actions

  • Governancehigh

    Related-party transactions at 5.2% of revenue

    Monitor: Annual report disclosures and auditor commentary.

  • Accounting qualitymedium

    Working capital cycle is long; growth consumes cash.

    Monitor: Cash-flow statement versus P&L each quarter.

Ongoing thesis monitoring

The thesis is a living position, not a one-time verdict

MetricCurrentlyThesis holds ifThesis breaks if
ROCE18.6%stays above 16%falls for two consecutive years
Cash conversion117%stays above 80%drops below 70% while revenue grows
Revenue growth9.7% CAGRtracks the 53% priced inslows for two quarters with no margin offset
Promoter holding26.1%stable or risingfalls sharply or fresh pledge appears

Peers in the same sector

Compare before sizing anything

Sun PharmaceuticalCipla

Data quality 58/100

Stated openly, as required by the product principles

  • • Fundamentals in this build come from a deterministic sample dataset, not licensed exchange filings.
  • • Segment, ownership and management figures are illustrative and must be verified against annual reports.
  • • Educational analysis only — not a recommendation to buy or sell any security.
  • • Accounting flags reduce the reliability of the reported profit base.